Canada Markets close in 2 hrs 49 mins

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.26+1.87 (+18.00%)
At close: 1:00PM EST

12.05 -0.21 (-1.71%)
After hours: 1:11PM EST

Full screen
Trade prices are not sourced from all markets
Previous Close10.39
Open10.49
Bid12.01 x 4000
Ask12.05 x 800
Day's Range10.52 - 12.40
52 Week Range2.28 - 33.79
Volume19,525,111
Avg. Volume16,068,717
Market Cap2.077B
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Why Inovio Stock Is Jumping Today
    Motley Fool

    Why Inovio Stock Is Jumping Today

    Shares of Inovio Pharmaceuticals (NASDAQ: INO) were jumping 10.5% as of 11:07 a.m. EST on Friday. Positive phase 2 results will also be necessary to advance the experimental COVID-19 vaccine into late-stage testing.

  • 3 Long-Shot Coronavirus Vaccine Stocks to Watch in December
    Motley Fool

    3 Long-Shot Coronavirus Vaccine Stocks to Watch in December

    Now that Moderna and Pfizer have both announced that their coronavirus vaccine candidates appear to be effective at preventing infection, distant laggards look less desirable than ever. Inovio Pharmaceuticals (NASDAQ: INO), Vaxart (NASDAQ: VXRT), and Novavax (NASDAQ: NVAX) aren't going to start selling their candidates to the public anytime soon, but they could still be lucrative stocks. All three have moved more slowly than Moderna and Pfizer, but they share one of the same challenges.

  • Why Inovio Stock Slid Today
    Motley Fool

    Why Inovio Stock Slid Today

    Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sliding 5.2% lower as of 3:45 p.m. EST on Friday. The company announced earlier in the day that positive results from a phase 2 study evaluating INO-5401 and INO-9012 in combination with cancer immunotherapy Libtayo will be presented at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting. In addition, investors appear to be much more heavily focused on Inovio's COVID-19 program than anything else right now.